New molecular biomarkers in differentiated thyroid carcinoma: Impact of miR-146, miR-221 and miR-222 levels in the evolution of the disease.

A new interesting article has been published in Clin Endocrinol (Oxf). 2019 Jul;91(1):187-194. doi: 10.1111/cen.13972. Epub 2019 Apr 14. and titled:

New molecular biomarkers in differentiated thyroid carcinoma: Impact of miR-146, miR-221 and miR-222 levels in the evolution of the disease.

Authors of this article are:

Gómez-Pérez AM, Cornejo Pareja IM, García Alemán J, Coín Aragüez L, Sebastián Ochoa A, Alcaide Torres J, Molina Vega M, Clu Fernández C, Mancha Doblas I, Tinahones FJ.

A summary of the article is shown below:

OBJECTIVE: MircroRNAs (miR) are small, noncoding RNA molecules of 18-25 nucleotides. Their dysregulation has been widely studied in many human tumours including differentiated thyroid cancer (DTC). miRs more frequently associated with these kinds of tumours are miR-146, miR-221 and miR-222. Our objective was to assess the relationship among circulating miR levels and the evolution and outcomes of disease.DESIGN: We analysed a sample of 60 patients with DTC assigning them to one of three groups according to the dynamic scale of risk (excellent response, incomplete biochemical response and incomplete structural response).PATIENTS AND MEASUREMENTS: At study inclusion, we determined thyroid-stimulating hormone, thyroxine, thyroglobulin, antithyroglobulin antibodies and plasma levels of miR-146, miR-221 and miR-222.RESULTS: Male sex and advanced age at diagnosis were associated with the worst disease progression. miR-222 was twofold to threefold higher in tall cell papillary carcinomas (P = 0.038). miR-146 (P = 0.016) and miR-221 (P = 0.050) had a positive correlation with thyroglobulin at the time of sampling. In regression analysis, miR-146 (P = 0.006), miR-221 (P = 0.004) and miR-222 (P = 0.007) predicted more than 70% of the variation in thyroglobulin levels at the time of sampling.CONCLUSIONS: Elevated miR-222 and miR-146 levels are associated with poorer outcomes of the disease and may have a prognostic value in the management and follow-up of DTC.© 2019 John Wiley & Sons Ltd.

Check out the article’s website on Pubmed for more information:

[link-preview url=https://www.ncbi.nlm.nih.gov/pubmed/30887564 forceshot=true]

This article is a good source of information and a good way to become familiar with topics such as: circulating microRNAs;differentiated thyroid cancer;miR-146;miR-221;miR-222;microRNAs;prognostic.

New Chemicals from MOLECULAR DEPOT


New Proteins from MOLECULAR DEPOT


New Antibodies from MOLECULAR DEPOT


New Research Kits from MOLECULAR DEPOT

Molecular Depot

Your specialty peptide, proteins, antibodies and chemical compounds store.